second and third look laparoscopy in pt4 colon cancer patients for early detection of peritoneal metastases

Conditions: Colorectal Cancer; Peritoneal Metastases

Summary: the colopec ii multicentre randomized trial will investigate the role of second and third look laparoscopy to detect metachronous peritoneal metastases at a clinically occult stage during the follow-up of pt4 colon cancer patients. it is expected that detection of pm at a clinically occult stage will translate into survival benefit, due to higher percentage of patients eligible for curative intent treatment with cytoreductive surgery (crs) and hyperthermic intraperitoneal chemotherapy (hipec).

problem description approximately 20-30% of patients with pt4 colon cancer develop peritoneal metastases (pm). the only proven curative option for macroscopic pm is cytoreductive surgery (crs) followed by hyperthermic intraperitoneal chemotherapy (hipec), but the efficacy and morbidity highly depend on the extent of peritoneal involvement. unfortunately, due to restricted accuracy of imaging modalities and the absence of early symptoms, pm are often detected at a stage in which only about 20-25% of patients are eligible for crs+hipec, and even these patients appear to have a relatively high peritoneal cancer index (pci). new diagnostic strategies are urgently required to detect pm at an early stage, resulting in a higher percentage of patients eligible for crs+hipec, which will translate into better survival because of the uniformly reported direct association between pci and survival. proposed solution preliminary findings of the colopec trial (nct02231086) revealed that pm were already detected at intentionally adjuvant hipec within 2 months after resection of the primary tumour in 10% of patients with pt4 colon cancer. based on these findings and literature, second look diagnostic laparoscopy (dls) to detect pm when the disease is still potentially curable by crs+hipec may be considered as an essential component of early follow-up of pt4 colon cancer. this needs confirmation in a larger patient cohort before implementing this in practice. furthermore, metachronous pm develop later on (\>12 months) in an additional 15-20% of the patients. these patients will be missed by a second look dls and might therefore benefit from a third look dls later on, which will be investigated in the colopec ii trial. objective the primary aim of this study is to determine the added value of third look dls after a negative second look dls in pt4 colon cancer patients to detect pm at a clinically occult stage. study design this is a randomized multicentre trial in which eligible patients will have routine ct-abdomen at 6 months postoperative (+3 months for those still treated with adjuvant chemotherapy), followed by second look dls within 1 month after ct if no pm or other metastases not amenable for local treatment are detected. patients without pm found during second look dls will subsequently be randomized between routine follow-up including ct-abdomen at 18 months in the control arm, or an experimental arm with a third look dls provided that pm or incurable metastases are absent at the 18 months ct-abdomen. the primary endpoint of the study is the proportion of pm detected after negative second look dls. the primary endpoint will be determined at 20 months. study population patients aged 18-80 years who underwent intentionally curative resection of pt4a,bn0-2m0 colon cancer or rectosigmoid cancer above the peritoneal reflection, either with or without adjuvant systemic chemotherapy, who are fit enough and surgically accessible to undergo second look dls between 6-10 months postoperatively and subsequent treatment of pm if detected. intervention dls will be performed in patients not already diagnosed with pm and without other metastases that impede curative intent treatment. access to the abdominal cavity is obtained under general anaesthesia by open introduction away from areas of expected adhesions, followed by adhesiolysis if necessary. complete staging of the intra-abdominal cavity is performed, with biopsy of any lesion suspicious of pm, and determining the pci for those patients with suspected pm. expected outcome it is hypothesized that in patients who had a negative second look dls, pm become clinically apparent in 5% until 20 months postoperatively with routine follow-up. a third look dls following a negative ct-abdomen at 18 months postoperative is expected to detect an additional 10% of pm. it is expected that detection of pm at a clinically occult stage will translate into survival benefit, based on the observation that survival rates after crs+hipec are higher if the pci is lower.

Eligibility criteria:
inclusion criteria: * curative intent resection of pt4a,bn0-2m0 colon cancer or rectosigmoid cancer above the peritoneal reflection, with or without adjuvant systemic therapy; * age between 18 and 80 years; * written informed consent. exclusion criteria: * histological subtype other than (mucinous) adenocarcinoma or signet-ring cell carcinoma; * clinical condition that does not allow for second look surgery or subsequent treatment of pm if detected; * second look surgery thought not to be technically possible (i.e. because of extensive abdominal surgery / re-interventions).

Keywords: pt4 colon cancer peritoneal metastases early detection diagnostic laparoscopy second look surgery third look surgery